In this cohort study of 199 patients with advanced nonlung cancers treated with anti–programmed cell death 1 antibody monotherapy, patients with preexisting interstitial lung abnormalities had significantly increased risk of immune checkpoint inhibitor induced–interstitial lung disease. The gene discussed is PDCD1; the disease is cancer.